Form 4: MYGN CSO Muzzey Reports RSU Vesting & Tax Withholding

Myriad Genetics Chief Scientific Officer Dale Muzzey reported the vesting of restricted stock units and subsequent share disposals for tax obligations.

Summary

• Dale Muzzey, Chief Scientific Officer of Myriad Genetics Inc. (MYGN), reported transactions related to his beneficial ownership.
• On March 12, 2026, Muzzey acquired 173,196 shares of common stock at a price of $0, stemming from the vesting of time-based restricted stock units.
• These time-based restricted stock units vest in three equal annual installments, beginning on the first anniversary of the grant date.
• Between March 13 and March 15, 2026, Muzzey disposed of a total of 37,799 shares of common stock at a price of $4.66 per share.
• These disposals were solely to satisfy tax withholding obligations associated with the vesting of both time-based and performance-based restricted stock units.
• The number of shares withheld for tax purposes was determined based on the closing price of Myriad Genetics' common stock on March 13, 2026.
• Following these transactions, Muzzey's direct beneficial ownership stands at 329,275 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The vesting of RSUs is a positive for the executive, indicating earned compensation, while the sale for tax purposes is a standard, non-discretionary transaction.

Positives

• The acquisition of 173,196 shares at $0 indicates the vesting of restricted stock units, representing a compensation benefit for the Chief Scientific Officer.
• The vesting of performance-based restricted stock units suggests the achievement of specific performance targets by the company or the individual.

Negatives

• The disposal of 37,799 shares, while for tax purposes, reduces the Chief Scientific Officer's direct beneficial ownership in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transaction filings like this Form 4 are routine disclosures for public company executives. The vesting of restricted stock units and subsequent share sales for tax purposes are common occurrences in executive compensation structures across the biotechnology and diagnostics industry, reflecting the realization of long-term incentives.

Stakeholder Impact

• Shareholders: The slight reduction in the Chief Scientific Officer's direct ownership due to tax withholding is a minor dilution, but the overall vesting indicates continued executive alignment with company performance.
• Employees: The vesting of RSUs demonstrates the company's compensation structure for executives, which can be a benchmark for other employees with similar equity incentives.

Next Steps

• Future annual installments of the time-based restricted stock units will vest on subsequent anniversaries of the grant date.

Key Dates

Recommendation

This Form 4 filing details routine compensation-related transactions by a company officer, specifically the vesting of restricted stock units and subsequent sales to cover tax obligations. These are non-discretionary events and do not reflect a change in the officer's investment conviction or the company's fundamental outlook. Therefore, it provides no new information that would warrant a change in an investor's current position, maintaining a 'hold' recommendation.

Keywords

Myriad Genetics, MYGN, Dale Muzzey, Chief Scientific Officer, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Compensation, Tax Withholding, Beneficial Ownership